10 tips on performing economic evaluation in kidney disease

Area of Science:

• Nephrology
• Health Economics
• Clinical Research

Background:

• Nephrology has seen advancements in clinical evidence for treatments and care models.
• There's a growing need for economic evaluations in kidney disease to guide reimbursement and healthcare spending.
• Cost-effectiveness analysis is vital for optimizing patient care within financial constraints.

Purpose of the Study:

• To highlight the importance and methodology of economic evaluations in kidney disease.
• To guide the development and adoption of new kidney treatments and care approaches.
• To ensure healthcare spending is optimized while improving patient outcomes.

Main Methods:

• Cost-effectiveness analysis estimating quality-adjusted life years (QALYs) and costs over patient lifetimes.
• Integrating data from clinical trials, health service research, and real-world evidence.
• Considering factors like disease progression, competing risks (cardiovascular disease, death), and subgroup analyses.

Main Results:

• Economic evaluations are essential for informed decision-making in kidney disease.
• Accurate cost-effectiveness requires comprehensive data and long-term extrapolation.
• Addressing specific populations and competing risks is crucial for unbiased estimates.

Conclusions:

• Economic evaluations are key to adopting new kidney treatments and optimizing healthcare budgets.
• Methodological rigor, including stakeholder input and diverse data sources, is vital.
• Understanding decision-maker perspectives enhances the impact of cost-effectiveness findings.